U.S. doctors had hesitated for 25 years to make the plunge, but last week they finally did. The U.S. Public Health Service announced that it had decided to make a big-scale test of BCG,* the anti-tuberculosis vaccine. Somewhere in the South, in a community with a high T.B. deathrate, PHS will soon have under way the first U.S. experiment in community-wide immunization against T.B. by vaccinating 100,000 people.
BCG vaccine is made from weakened tubercle bacilli. It immunizes by building up a person's resistance through a mild infection.
Despite its wide use abroad (in Denmark, Norway, Russia, Canada, South America), U.S. authorities...
To continue reading:
or
Log-In
